Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 23 of 23 publications.
Skip to main content
Gilsenan A, Midkiff K, Harris D, McQuay L, Hunter S, Kellier-Steele N, Andrews E. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data. Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1616-26. doi: 10.1002/pds.5103
Gilsenan A, Harris D, Reynolds M, McSorley D, Midkiff K, Jackson L, Muldavin B, Kellier-Steele N, Andrews E. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int. 2020 Nov 5;32(4):645-51. doi: 10.1007/s00198-020-05718-0
Gutierrez L, Danysh HE, Aguado J, Hunt PR, Kaye JA, Garcia-Albeniz X, Gilsenan A. Value of adding secondary read diagnosis codes to identify breast cancer and bladder cancer in the Clinical Practice Research Datalink: a pilot validation study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Danysh HE, Gilsenan A, Beachler DC, Kaye JA, Garcia-Albeniz X, Schmid R, Hunter S, Hunt PR, Aguado J, Calingaert B, Layton JB, Gutierrez L. Validation of breast cancer and bladder cancer among patients with type 2 diabetes mellitus in Medicare: a pilot study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Layton JB, Zhou CK, Danysh HE, Bleachler DC, Ziemiecki R, Dinah J, Yin R, Calingaert B, Hunt PR, Gilsenan AW, Johannes CW. Identifying cohorts of patients with type 2 diabetes mellitus initiating dapagliflozin in three data sources. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Dinh J, Danysh HE, Johannes C, Gutierrez L, Schmid R, Arana A, Kaye JA, Pladevall-Vila M, Garcia de Albeniz X, Hunt PR, Gilsenan A, Beachler DC, Ke Zhou C. Description of acute kidney injury and breast cancer outcome validation processes across three databases. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Morrato E, Smith M, Auth D, Gilsenan A. Effective risk management: best practices for designing, implementing, and evaluating risk minimization programs. Presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.
Danysh HE, Layton B, Beachler DC, Arana A, Pladevall-Vila M, Schmid R, Calingaert B, Ziemiecki R, Hunt PR, Gilsenan A, Johannes C. Validation of acute outcomes among patients with type 2 diabetes mellitus in Medicare: a pilot study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.
Gilsenan A, LaCivita C. Practical considerations for robust evaluation of risk minimization programs: regulatory, industry, service provider insights. Presented at the 2020 DIA Virtual Conference; June 14, 2020. Washington, DC.
Molfino NA, Averell CM, Hahn B, Zografos L, Gilsenan A, Richardson D, McSorley D, Slade DJ. Real world evidence in asthma: pulmonary function and asthma control in respiratory specialty clinics in the US. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 20, 2020. Philadelphia, PA.
Molfino NA, Averell CM, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Slade DJ. Patients with uncontrolled asthma eligible for a biologic. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 20, 2020. Philadelphia, PA.
Averell CM, Hahn B, Zografos L, Gilsenan A, Richardson D, McSorley D, Molfino NA, Slade DJ. Assessment of asthma control in respiratory specialist offices in the US. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 17, 2020. Philadelphia, PA.
Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res. 2020 Feb;36(2):244-51. doi: 10.1002/jbmr.4188
Rebordosa C, Houben E, Laugesen K, Bothner U, Montonen J, Aguado J, Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW. No evidence of off-label use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: a drug utilization study. Sci Rep. 2020 Jan 17;10(1):586. doi: 10.1038/s41598-019-57397-5
Gilsenan AW. Depression and pain in the primary care setting. Presented at the Correlation Between Depression and Pain: Creating a New Treatment Paradigm to Evaluate Cost and Caliber of Care. Symposia at the Academy of Managed Care Pharmacy 2002 Educational Conference; October 2002. Washington, DC.
Andrews EB, Mitchell AA, Seligman P, Cook SF, Gilsenan AW. Risk management: what are we driving, where are we going, and how will we know when we get there? Presented at the 18th International Conference on Pharmacoepidemiology; August 2002.
Longo C, Raskin J, Gilsenan AW, Corey-Lisle P, Hopkins JS, Sherrill BH. Prevalence of treatment-resistant depression in Saskatchewan - limitations of a claims-based analysis. Int J Neuropsychopharmacol. 2002 Jun 1;5(Suppl 1):S141. doi: 10.1017/S1461145702003176
Longo CJ, Raskin J, Gilsenan AW, Corey-Lisle P, Sherrill EH, Hopkins JS. Prevalence of treatment-resistant depression in Saskatchewan—limitations of a claims based analysis. Poster presented at the XXIII CINP Congress; 2002.
West SL, Dever JA, Troutman KS, Gilsenan AW, Glasser D. Methodology for conducting a national population-based prevalence study of erectile dysfunction. Poster presented at the 18th International Conference on Pharmacoepidemiology; 2002.
Gilsenan AW, Hopkins JS, Sherrill EH, Corey-Lisle PK, Longo CJ, Raskin J. Prevalence and costs of treatment-resistant depression in a Canadian claims database. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2002.
Pendergast KB, Gilsenan AW, West SL, Swindle RW, Kroenke K. Differences in psychological and other quality of life dimensions in depressed patients identified as low-risk or high-risk for suicide. Poster presented at the 18th International Conference on Pharmacoepidemiology; 2002.
Von Scheele BG, Sherrill EH, Gilsenan AW, Devlin P. Therapeutic interchangeability of levothyroxine. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2002.
Hopkins JS, Gilsenan AW, Sherrill EH, Cory-Lisle PK, Longo CJ, Raskin J. Methods to identify treatment-resistant depression in a Canadian claims database. Poster presented at the International Society for Pharmacoepidemiology Conference; 2002.